tiprankstipranks
COSMO Pharmaceuticals N.V. (GB:0RGI)
LSE:0RGI
Holding GB:0RGI?
Track your performance easily

COSMO Pharmaceuticals N.V. (0RGI) Income Statement

5 Followers

COSMO Pharmaceuticals N.V. Income Statement

Last quarter (Q4 2022), COSMO Pharmaceuticals N.V.'s total revenue was €―, a decrease of ― from the same quarter last year. In Q4, COSMO Pharmaceuticals N.V.'s net income was €―. See COSMO Pharmaceuticals N.V.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-€ 102.09M€ 65.07M€ 60.95M€ 62.49M€ 65.62M
Cost of Revenue
-€ 18.76M€ 15.14M€ 10.44M€ 9.25M€ 6.22M
Gross Profit
-€ 83.33M€ 49.93M€ 50.51M€ 53.25M€ 59.40M
Operating Expense
-€ 55.27M€ 38.83M€ 43.60M€ 65.56M€ 76.02M
Operating Income
-€ 28.06M€ 11.10M€ 6.91M€ -12.31M€ -16.62M
Net Non Operating Interest Income Expense
-€ -6.33M€ -6.41M€ -7.16M€ -7.75M€ 1.15M
Other Income Expense
------
Pretax Income
-€ 24.47M€ 24.00M€ -6.93M€ -21.30M€ -17.46M
Tax Provision
-€ 6.97M€ 2.33M€ 970.00K€ 3.19M€ 598.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ 17.23M€ 21.67M€ -7.90M€ -24.42M€ -18.01M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-€ 120.00K€ 117.00K€ 102.00K€ 186.00K€ 1.94M
Total Expenses
-€ 74.03M€ 53.97M€ 54.04M€ 74.80M€ 82.24M
Net Income From Continuing And Discontinued Operation
-€ 17.23M€ 21.67M€ -7.90M€ -24.42M€ -18.01M
Normalized Income
-€ 17.24M€ 21.78M€ -7.69M€ -26.46M€ -16.71M
Interest Expense
-€ 9.16M€ 8.99M€ 8.73M€ 8.83M€ 1.04M
EBIT
-€ 33.63M€ 32.99M€ 1.80M€ -12.47M€ -16.41M
EBITDA
-€ 47.49M€ 40.36M€ 7.84M€ -6.72M€ -11.93M
Currency in EUR

COSMO Pharmaceuticals N.V. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis